Pliant Therapeutics, Inc.
PLRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $447 | $0 | $0 |
| Gross Profit | $0 | -$447 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $17,938 | $32,198 | $43,436 | $38,793 |
| G&A Expenses | $10,331 | $13,394 | $15,499 | $14,527 |
| SG&A Expenses | $10,331 | $13,394 | $15,499 | $14,527 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$447 | $0 | $0 |
| Operating Expenses | $28,269 | $45,145 | $58,935 | $53,320 |
| Operating Income | -$28,269 | -$45,592 | -$58,935 | -$53,320 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,968 | $2,292 | $2,769 | $3,588 |
| Pre-Tax Income | -$26,301 | -$43,300 | -$56,166 | -$49,732 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26,301 | -$43,300 | -$56,166 | -$49,732 |
| % Margin | – | – | – | – |
| EPS | -0.43 | -0.71 | -0.92 | -0.82 |
| % Growth | 39.4% | 22.8% | -12.2% | – |
| EPS Diluted | -0.43 | -0.71 | -0.92 | -0.82 |
| Weighted Avg Shares Out | 61,406 | 61,386 | 61,223 | 60,539 |
| Weighted Avg Shares Out Dil | 61,406 | 61,386 | 61,223 | 60,539 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3,101 | $3,568 | $4,422 |
| Interest Expense | $2,783 | $809 | $799 | $834 |
| Depreciation & Amortization | $436 | $447 | $448 | $458 |
| EBITDA | -$23,082 | -$42,044 | -$54,919 | -$48,440 |
| % Margin | – | – | – | – |